GlassScriptPhysician profile
Geeteshwar S Mangat
NPI 1447575097
$1,128.79
in general payments reported to CMS, 2019-2025
20 companies · $545 in 2025
The $545 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.96 · 2021: $60.67 · 2022: $19.93 · 2024: $429 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $140.24 | 2024 | Arexvy, Trelegy Ellipta |
| Silk Road Medical, INC. | $135.37 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Astrazeneca Pharmaceuticals LP | $119.62 | 2024-2025 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $110.91 | 2021-2025 | Spravato |
| Abbvie INC. | $87.55 | 2025 | |
| Pfizer INC. | $76.12 | 2019-2025 | |
| Novo Nordisk INC | $64.48 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.44 | 2024-2025 | Jardiance |
| Dexcom, INC. | $47.34 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $38.56 | 2025 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $34.55 | 2025 | |
| Phathom Pharmaceuticals, INC. | $34.31 | 2024-2025 | Voquezna |
| Currax Pharmaceuticals LLC | $33.55 | 2025 | Contrave |
| Lilly USA, LLC | $33.36 | 2025 | Jardiance, Zepbound, Mounjaro |
| Astellas Pharma US INC | $32.81 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $21.50 | 2024 | Yupelri |
| Thea Pharma INC. | $18.92 | 2024 | Iyuzeh |
| Abiomed | $18.59 | 2025 | |
| Corcept Therapeutics | $16.46 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geeteshwar Mangat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.